#IgG deficiency

[under-same-sky]

🥳🥳

I'm really happy.. feels like an understatement I have been heard And we are investigating my shit immune system!!

🥳🥳

😅For those that want the deets😅

I met with my new Hematologist.

He wanted to go over my ITP history FROM THE BEGINNING! He was shocked how much I had in my head without notes.

I told him what treatments have yielded no platlet responses over the years and how most my drops since 2013 have been immune system triggered or medication triggers (like vaccinations)

He wanted me to take a daily med that stimulates the bone marrow to produce more platlets but these meds have only been out 10 years and were approved as orphan drugs. I have followed these meds the last ten years. I'm not on board with these. MORE SO, I DO NOT have Chronically low numbers. Mine are event drops.

This HOUR long, one on one appointment with him ended with him agreeing that

* I am on top of this

*I manage this condition well

*I can have IVIG infusions when i drop below 20

AND! AND!

since it's tied so to my immune system,

My severe infection history & routine home mitigation, & I respond SO WELL to IVIG w/o roids I am being sent to the immunology department to be checked for IgG Deficiency, CVID & other autoimmune issues. They will follow up with rheumatology should they find anything but both referral sent.

I already have intake appointment with them! I know this isn't likely going to be a fast thing but the possibility of some answers and maybe not end up in the hospital when I get sinus infection or UTI would be really nice.

#itpwarrior #platelets #immune thrombocitopinia purpua #idiopathic thrombocytopenia #autoimmine disease #trachel stenosis #fibromyalgia #CVID #igg deficiency #ivig #iv infusion therapy

[1000creepyeyes]

IgG deficiency has me feeling blah 😑

#life of eyes #igG deficiency

[drpedi07]

Igg Subclass Deficiency

IgG subclass deficiency is a type of primary immunodeficiency where subclasses of IgG are deficient leading to recurrent infections. 

#Igg #Subclass #Deficiency #Immunodeficiencies

[honeysuckle-venom]

I got a bunch more blood tests back, and although I am not a doctor and don't know anything for sure, I do know how to use google. My immunoglobulin-g and immunoglobulin-a were both low. Apparently, immunoglobulin-g is responsible for fighting off both bacterial and viral infections, and people with IgG deficiency are significantly more likely to get recurrent and/or severe infections. Finally, finally, finally after two years of recurrent skin infections and dozens of courses of antibiotics I might have an ANSWER for why this keeps happening. I'm so incredibly happy right now. The daily showers, bleach baths, hibiclens baths, prescription lotion, prescription ointment, antibiotics, NONE of it has worked and every time I've asked a doctor they've just been like "well that sucks, try washing even more." But maybe there IS a reason and therefore something to be done!!! I know that nothing is certain and I need to talk to an actual doctor about it but this is the first glimmer of hope I've seen, I'm so incredibly relieved and excited.

#text post #my post #it would also explain why i'm so sickly and just seem to catch stuff alll the time #like i said i don't know anything for sure. need to talk to a dr about results not just google. but this seems really plausible #medical cw #in other news still more inflammation markers were elevated. big surprise

[silenthillbunni]

yk to really drive home the point of how worthless i am.... i've always wanted to donate blood, but i have igg & iga deficiency so im not even allowed to donate blood bc my blood is tainted :)

#i also have a more rare blood type so it would've been helpful to others #but nope! im tainted

[sleeping-satan]

I'm depressed and I'm going to use one of my many coping mechanisms: Research a random topic that is part of my distress.

Shit I'm finding about mixed IBS, because doctors actually can't simply give me a prescription and it's helped I have to constantly experiment with different methods which are costly, painful, and time-consuming.

IBS is the second most common reason for missing work besides the common flu

Women with mixed IBS improve more from "Igg Food Antibody Guided Elimination-Rotation Diet" (removing specific trigger foods and slowly reintroducing them) than they do with a low FODMAP diet in this study - As someone who has tried the low FODMAP diet, some of my trigger foods are low FODMAP, some foods are trigger foods in certain brands, and some high FODMAP foods are actually safety foods for me (cinnamon raisin bagels). No men were in the study, so it's not generalizable to them, but it also doesn't leave out the possibility that the same would not work.

Propolis supplementation (propolis is basically bee glue, bees make it from tree buds) may help with IBS-C and IBS-M. The main risk of propolis is an allergic reaction that usually comes from people who are allergic to other bee products.

"The most controversial features of the low FODMAP diet are its short- and long-term limitations (a high level of restriction, the need for monitoring by an expert dietitian, potential nutritional deficiencies, significant gut microbiota reduction, lack of predictors of response), as well as the potential lack of advantage over alternative dietary, pharmacological and psychological interventions for IBS" - It's also downright unaffordable. Glucose-free products are triple the cost of regular ones, meat is one of the low fodmap foods that can mainly be used and that's costly, etc. Also, who the fuck has money for a dietician?

"Newer epidemiological studies [52] have found out that, in almost half of the patients, intestinal symptoms appear first and mood disorders after, probably because the gut disturbances send signals to affect the brain. Likewise, in another study, psychiatric patients who also had IBS reported that they developed their psychiatric symptoms after they were diagnosed with IBS [53]." [Link] - this is also personally relevant to me as I've had IBS all my life but was diagnosed with mental health issues later on, and my IBS makes my stress and depression worse from pain, bloating, etc.

This comes from the same link as before, but I sadly have had three of these and have had further testing done for them, so "alarming features" is apparently my IBS being spicy.

I was on the toilet for a good portion of this post

#ibs #ibs mixed #random shit #science side of tumblr #because why not

[ghostdata]

pcp: your white blood cell count is high im sending you to a hematologist

hematologist: your fat and a smoker

pcp months later: well you have some weird blood work still but that must be your baseline 🤷‍♂️

psychiatrist: wtf your blood work is weird im ordering tests

blood tests: your igg deficient

me: 🙄



#im so tired #im debating changing pcp depending what he says abt this

[helthcareheven]

VitaImmuno pH4: Intravenous Immunoglobulin Potency

Introduction Human immunoglobulin, also known as intravenous immunoglobulin or IVIG, is a therapeutic preparation of pooled human immunoglobulins obtained from the plasma of healthy donors. It contains a balanced mixture of immunoglobulin G antibodies against various infectious agents. IVIG therapy aims to replace the missing antibodies in patients with primary or secondary immunodeficiencies. This article discusses the composition, mechanism of action, indications and administration of pH4-adjusted IVIG.

Composition IVIG contains mainly immunoglobulin G (IgG) antibodies extracted from donated human plasma by fractionation processes. It consists of over 95% intact IgG molecules with traces of IgA and IgM. The immunoglobulins in IVIG have specific pathogen-directed antibodies against bacteria and viruses that infect humans. The IgG antibodies are polyclonal, which means they contain a wide variety of antibodies that react against various microorganisms. The pH4-adjusted formulation of IVIG has a neutral pH between 4-5 to reduce the risk of acute kidney injury.

Mechanism of Action Human Immunoglobulin (pH4) for Intravenous Injection works through multiple mechanisms to boost the immune system. It replaces the missing antibodies in immunodeficient patients by providing passive immunization against pathogens. The exogenous IgG antibodies bind to Fc receptors on phagocytes, B cells, and other immune cells to facilitate opsonization and elimination of infectious agents. IVIG also modulates the immune system by inhibiting pro-inflammatory cytokines, complement activation, and Fc receptor-mediated phagocytosis. These immunomodulatory effects help control autoimmune and inflammatory conditions.

Indications IVIG therapy is recommended for treatment and prevention of infections in patients with primary immunodeficiencies like common variable immune deficiency, X-linked agammaglobulinemia and hypogammaglobulinemia. It is also a first-line treatment for certain autoimmune diseases like Kawasaki disease, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. IVIG reduces symptoms and relapses in these conditions by dampening pathological autoantibody production and cytotoxic immune responses.

Administration IVIG is administered intravenously through a peripheral or central line at regular intervals. The dosage varies depending on the indication and ranges between 300-600 mg/kg given every 3-4 weeks or every 2-6 months for replacement therapy in primary immunodeficiencies. Frequent dosing is required initially for treatment of autoimmune and inflammatory conditions. IVIG is usually well-tolerated but some common adverse effects include headache, nausea, fever, chills and abdominal pain which can be managed symptomatically. Rare complications include thromboembolic events, aseptic meningitis and acute kidney injury. Careful infusion with hydration and dose monitoring helps minimize risks.

Mechanism of Action As described earlier, IVIG exerts its immunomodulatory and anti-inflammatory effects through multiple mechanisms. A major mechanism involves modulation of the Fc portion of IgG molecules. IVIG engages inhibitory Fcγ receptors (FcγRIIB) on immune cells, decreasing their activation threshold. This suppresses pro-inflammatory cytokine release and phagocytosis. IVIG also competes for binding to activating Fcγ receptors, further inhibiting immune cell activation. At the same time, exogenous IgG provides opsonization of pathogens via activating FcγRs to enhance elimination.

Additionally, IVIG binds specifically to certain cytokines and complement factors to inhibit their activity. It neutralizes interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α and interferon (IFN)-γ which play a key role in chronic inflammation. IVIG also downregulates expression of adhesion molecules and secretion of chemokines involved in immune cell trafficking to sites of inflammation. By blocking complement activation at the C3 convertase level, IVIG prevents membrane attack complex formation and tissue damage in autoimmune diseases. These diverse suppressive mechanisms help control excessive immune responses and inflammation in various conditions treated with IVIG.

Efficacy and Clinical Trials The efficacy and safety of IVIG has been validated through extensive clinical research over the past few decades. In primary immunodeficiencies, long-term IVIG therapy greatly improves survival by preventing life-threatening bacterial infections. For Kawasaki disease, a randomized controlled trial showed IVIG plus aspirin led to a significantly lower coronary artery aneurysm rate compared to aspirin alone.

Some notable clinical trials in other conditions include a trial demonstrating that IVIG prevented relapse in Guillain-Barré syndrome; a large trial confirming clinical improvement and reduced relapses with IVIG versus placebo in chronic inflammatory demyelinating polyneuropathy; and trials establishing efficacy of IVIG in idiopathic thrombocytopenic purpura and multifocal motor neuropathy. Ongoing research continues to explore new potential uses of Human Immunoglobulin (pH4) for Intravenous Injection in various autoimmune and inflammatory diseases.

#ImmunovateIV #IntravenousStrength #ImmunoRevitalize

[meditating-dog-lover]

Eczema update 03/23

So I felt quite nauseous and lightheaded today. I did not have any gastrointestinal discomfort, just dizzy and nauseous and lightheaded, which still is not fun at all. I'm feeling better now, thankfully. I don't know what caused it, sometimes stuff like this just happens. It may or may not be due to the liver supplement I've been taking. I really hope it isn't because I have high hopes that this supplement will really help my skin. I'm going to continue taking it, but if I start to feel worse over the days, then I will quit. But I really hope that doesn't happen.

I was going to break my fast this morning, though my dog came to me signalling that he wants to walk. So I walked him, and that walk turned out to be 45 minutes and I was pretty hungry. I don't know if that played a role, or if I have low blood pressure, or if it's something I ate. Again nausea can come out of nowhere sometimes, maybe I'm exhausted. But I'm better now and was able to shower, walk my dogs, eat, take my supplements and drink water. Because I wasn't feeling well, I ate late and went beyond my feeding window (~10 PM), which is completely fine because I had a medical reason.

I know my supplement I'm taking now is great for liver health, as well as not drinking. However inflammatory foods, especially though high in omega-6 fats and sugar, can be taxing on the liver. Following an anti-inflammatory diet can be great for both liver and skin health. NAFLD and other liver diseases can still happen even if you don't drink. A poor diet high in inflammatory foods like sugar and inflammatory fat sources can influence liver health poorly. I noticed my hands itch on the days where I ate out this week. It's not always about food sensitivities and IgG response, but inflammatory foods in general. Thankfully I eat pretty healthy overall and I don't drink, but I like to enjoy eating out here and there (especially on Fridays). That should be a way bigger focus than IgG triggering foods, at least for me. I want to eat healthy and have a diet filled with health grains, fruits, vegetables, healthy oils, nuts, seeds, and healthy dairy and animal products (lean proteins and health egg and butter sources as opposed to burgers and fried chicken which are fried in inflammatory oils). On the topic of oils, I love olive and avocado oil and I can consume these with no issues. So eating anti-inflammatory for the most part, as well as taking care of my liver and potentially my gut health (once I talk to my doctor and do the take home test) can help a lot.

And I really don't think tomatoes and cocamidopropyl betaine are the major culprits, it's definitely a deficiency in anti-inflammatory nutrients, an excessive consumption of inflammatory foods, poor liver health, and poor gut health. I take anti-inflammatory supplements like vitamin D, zinc, and flaxseed oil. And my diet is quite healthy, though I will notice some inflammation when I eat fried fatty foods, but they don't make up the bulk of my diet. That takes care of the diet part.

I'm still working on my liver health by taking the supplement. I won't take this longterm though, just something to give my liver some support. The liver is a powerful organ that plays a role in digestion and detoxing. It makes zero sense to do "detox" juices, cleanses, colonics, enemas, or anything else dangerous if your liver is in poor health. I do believe in "detoxing" methods such as fasting, eating healthy foods rich in fiber, drinking enough water, limiting my intake of inflammatory foods, and giving my detoxing organs support. If your diet is poor and you drink a lot of alcohol, both of which can compromise gut and liver health, then you will never give your body the chance to filter and rejuvenate.

I'm going to speak with my functional medicine doctor in 2 weeks so we can talk more about eczema in general and so I can do a gut health evaluation to see if there are any areas that need improvement. I know I can benefit from taking a regular gut health supplement and eating foods that support my health. However gut health supplements are one of the most confusing supplements to purchase. There are a ton out there and it's not clear what you really need. Do you need enzymes? Do you need HCl? Do you need bacteria? If so which strains and how many CFUs? Do you need gut lining support? Do you need fiber? It becomes so confusing and taking the wrong supplement will do more harm than good. I remember taking a probiotic I found in Ulta around 9 months ago and had the worst gastrointestinal discomfort, I had to immediately leave work. Other probiotics helped, and others did not make a difference.

I also had some pizza today, thankfully no inflammatory reaction to the tomato. Like I said, I doubt tomatoes are the culprit. I've been eating tomatoes all my life without reacting poorly to them. I'm still going to limit my consumption until my skin heals. And I'm going to use cocamidopropyl betaine-free products for a month so I can say I did it, and also until my skin heals. But the main focus here is to get enough anti-inflammatory nutrients through both diet and supplementation, to avoid/limit inflammatory foods, to give my liver support for proper physiological detoxification, and to address my gut health. I've been doing the first for a while, I'm working on the second and third points now, and I'll address my gut health in 2 weeks.

It is so cold here and my hands became dry and itchy. I wanted to rub them, but that will cause more inflammation. So I gently scratched them. I know scratching is a no-no, but gentle scratching is way better than forcefully rubbing the itchy area with a towel or my hands. I've been gently scratching any itchy areas I had. I do develop some scratches, which are not fun but are also way better than large swelling blisters and bloody, oozy skin due to forceful rubbing the area. It's the best solution I have now until the inflammation is gone.

I have high hopes now for my anti-inflammatory diet and liver supplements. I'm going to keep on taking the supplements for a month. I did experience some dizziness and nausea today, but I really hope it's not due to the supplement and even if it is, I hope it doesn't get too bad because I have high hopes that it will help my skin. I had stubborn patchy and inflamed spots that are healing this week, especially on my neck, chest, earlobe, mouth and right wrist. My skin is less red now, but my hands look dry and are slightly inflamed and itchy. If my skin is itchy, despite not being red, that means there is still some inflammation even if I cannot see it. So I'm going to continue the protocols I'm following now until my skin heals, soap-wise, diet-wise, and supplement-wise. Eventually I'll address my gut health and start taking a gut health supplement.

Of course I also need to work on stress management, because stress makes eczema worse. I'm going to therapy and journaling, and anxiety management is another health goal I have for this year. Regardless, I will heal my skin, and I already see it healing.

I'm at a point where I want to have net healing. Just like when I had my dental issues. There is demineralization on one end and remineralization on the other. When the balance is shifted to demineralization due to poor diet, poor oral hygiene care, fat soluble vitamin deficiencies, and mouth breathing, cavities will form. When the area of decay is very small, the area can remineralize through proper nutrition, hygiene, and addressing dry mouth. This will cause the small areas of decay to recalcify and the decay process stops (this is something an ethical dentist and hygienist will tell you). The same logic can be applied to my skin. I want a case where I want to shift the balance away from inflammation and towards healing. I may have some inflammation, I just want it to subside overtime by following an anti-inflammatory protocol. Then the inflammation and irritation will go away. My skin is slightly inflamed, but it's better than it was last week which is promising. I just need to give it more time as well as address my gut health and anxiety. Then I will heal.

[lethbarton82]

Modification: Preclinical antivenom-efficacy testing shows possibly disturbing deficiencies associated with snakebite treatment ability throughout Eastern Cameras.

Nevertheless, your integrity with the blood-brain barrier (Eee) had been basically preserved, while revealed by way of a deficiency of extravasation regarding IgG in to the brain parenchyma. To conclude, many of us, for the first time, demonstrate that functional cerebrovascular redesigning comes about around one month within db/db rats as well as the shortage in gliovascular direction be involved within cerebral hypoperfusion prior to Ddd break down in 16-week-old db/db these animals.Instantaneous arterial pressure-flow (or even rate) connections reveal the presence of the cerebral essential concluding strain (CrCP), together with the pitch from the romantic relationship indicated by the resistance-area product (Hip hop). Throughout 194 healthy themes (20-82 years, Ninety days feminine), cerebral the flow of blood speed (CBFV, transcranial Doppler), arterial blood pressure (BP, Finapres) as well as end-tidal Carbon (EtCO2, capnography) ended up assessed continually regarding a few minutes during quickly arranged variations involving Blood pressure while resting. The actual vibrant cerebral autoregulation (Florida) directory (ARI) was taken out using shift function evaluation through the CBFV action a reaction to the actual BP feedback along with step responses have been in addition attained for your BP-CrCP and also BP-RAP associations. ARI has been demonstrated to decrease as we grow old for a price of -0.025 units/year of males (p = 0.022), however, not in women (p = 0.Forty). The temporary styles of the BP-CBFV, BP-CrCP as well as BP-RAP stage responses ended up clearly depending the particular ARI (p  much less and then  0.0001), however, not through sex. Age group have also been a significant determinant of the maximum in the CBFV stage reaction along with the butt of the Hip hop result. Even though the Hip hop phase reply design will be in line with a new myogenic mechanism controlling energetic Florida, further tasks are necessary to explore the opportunity connection in the CrCP action response together with the flow-mediated element of autoregulation.Perivascular room makes it possible for cerebral interstitial water settlement. Nonetheless, it can be cloudy just how dilated perivascular space (dPVS) affects the particular interstitial h2o of encompassing bright matter. All of us targeted to discover the existence and degree associated with modifications in normal-appearing white-colored matter water parts around dPVS in numerous numbers. 20 balanced elderly topics and also 15 elderly subject matter using severe cerebral little charter yacht ailment (CSVD, with lacunar infarction 6 months before the check out) have been contained in the research. As well as other 28 balanced grown-up themes ended up enrolled under a diverse encoding parameter to determine if the results are usually similar. Your normal-appearing white make any difference around dPVS had been labeled straight into 10 levels (1 mm breadth every) depending on his or her long distance in order to dPVS. Many of us evaluated your indicate isotropic-diffusing volume of water portion in every covering. Many of us discovered a substantially reduced free-water articles thrombin signal inside the levels closely alongside the dPVS in the healthful elderlies. nevertheless, this particular lowering about dPVS had been weakened from the CSVD themes.

#inhibitor #small molecules #chemicals #kinase inhibitors #tyrosine kinase inhibitors #enzyme inhibitors #protein inhibitors #proteins kinase inhibitors #phosphatase inhibitors #compound library #activators #modulators #agonists #antagonists

[1000creepyeyes]

Hi! I’m Eisley. I’m a 28 year old disabled asexual lesbian from the east coast. I struggle with a slew of both mental and physical health conditions such as DID, PTSD, Degenerative Disk Disease, Meneire’s Disease with hearing loss and an IGG deficiency (etc.) I really need ya’ll’s help.

In short; my mother spent last weekend brainwashing me to the point of a nervous breakdown. I had my friends, sister and therapists all telling me the same thing but I’m really struggling with the events. I’m without any money and need a new phone before she turns this one off on me. I don’t know what’s real and what’s not rn. I don’t know what I should even do to help myself rn, just fuck. I feel so helpless. My mother screamed, called me a liar, manipulative, a monster; she fed me horror stories of all the “terrible things I’ve done to her” and the lingering reminder of something she used to say when I was a child “I brought you in this world, I can take you out!” I get that it’s a generational thing to say that, but it’s a little different bc while I don’t believe my mother would ever do anything by her own hand; I do believe she could bring me so low that I’d do it for her. I’m afraid if I don’t get a new phone figured out, I may have to confront her. If you’re unable to help financially, plz blaze/reblog this.

Ask for my cash app in my DM, thank you 💜

#life of eyes #brainwashing #mental health #mental abuse #emotional abuse #parents #financial help #why #ask for cashapp #plz help #actually ptsd #did system #cw sui mention #triggering themes #triggering content #mutual aid

[omkarpatel]

Human Immunoglobulin (pH4) for Intravenous Injection is Estimated to Witness High Growth Owing to Rising Prevalence of Neurological and Immunodeficiency Diseases

Human immunoglobulin (pH4) is a blood plasma derived product administered intravenously for treatment of various neurological and immunodeficiency diseases. It contains antibodies which help strengthen the body's natural defenses against infectious agents. The rising incidences of immune deficiency disorders like agammaglobulinemia and common variable immunodeficiency have inflated the demand for immunoglobulin therapy. The global Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 17.5 billion in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Rising prevalence of neurological and immunodeficiency diseases is estimated to witness high growth. Neurological disorders pose a significant healthcare burden globally and afflict millions worldwide each year. conditions like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy require intravenous immunoglobulin as a mode of treatment. According to the World Health Organization, over 1 billion people suffer from some form of neurological disorder. The annual cost of neurological conditions in the U.S. alone is estimated to be over $800 billion. Thus, the growing cases of neurological diseases will spur demand for immunoglobulin therapy, acting as a high impact rendering driver for the market.

Porter’s Analysis Threat of new entrants: Low barrier to entry due to availability of raw material and manufacturing process knowledge. However, high capital requirements for production facilities and strong brand loyalty towards existing players limits threat. Bargaining power of buyers: Moderate bargaining power due to presence of substitutes. However, specialized production process results in inelastic demand. Bargaining power of suppliers: High dependence on plasma suppliers limits bargaining power. Suppliers can charge higher prices or refuse supply during shortages. Threat of new substitutes: Low threat as IgG products have no close substitute for treatment of certain immune disorders and deficiencies. Substitution requires regulatory approval and clinical trials. Competitive rivalry: Intense competition between major players. Companies compete based on product quality, reliability of supply, price and brand reputation. SWOT Analysis Strength: Established production facilities and regulatory approvals. Diversified product portfolio to treat range of conditions. Weakness: High capital intensity of production and vulnerability to plasma supply disruptions. Stringent regulatory norms increase compliance costs. Opportunity: Expanding patient population and increased diagnosis rate in developing regions. New clinical indications can boost revenue streams. Threats: Price controls and government reimbursement policies. Stringent import and export regulations across countries. Key Takeaways The global Human Immunoglobulin (pH4) for Intravenous Injection market is expected to witness high growth. The market is dominated by North America owing to high prevalence of immunodeficiency and autoimmune disorders. Rising healthcare spending and presence of major players in the US and Canada will drive the region's market share. Europe is the second largest regional market led by countries such as Germany, UK and France. Higher acceptance of IgG therapies and supportive national health strategies supplement the regional growth. Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection market are CSL Behring, Grifols, Baxter, Octapharma, Kedrion, CNBG, Hualan Bio and BPL. These players acquire plasma from approved donors and fractionate to produce standard and specialized IgG formulations.

#healthcare

[storiesofasicko]

i've been dealing with an allergy to all antibiotics, NSAIDs, steroids, OTC painkillers, contrast dye, and RX opioids.

also allergic to: my dentalwork (crowns), dental metals, dental compounding material, heavy metals like nickel and copper. had to switch cookware to all-glass Pyrex. eating a low-nickel, low oxalate, low-histamine d*et since january 2023.

definitely DAO-deficient. taking the following each day:

4.2 mg DAO before meals

quercetin, 800mg

bromelain, 165mg

n-acetyl-cysteine, 600mg

fish oil, 2100mg

bovine colostrum, 2000mg

immunoglobulin (IgG) 800mg

a bunch of H1 & H2 oral antihistamines

dupixent 300mg every other week aka every 14 days, but my insurance has such a hefty copay, i cannot afford every dose, even with dupixent's financial assistance program.

#chronically ill #mcas #take your meds #ibs

[medicaregate]

Wiskott-Aldrich Syndrome | Causes, Symptoms & Treatments

Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency that is characterized by eczema, recurrent infections, and micro-thrombocytopenia.

Wiskott-Aldrich syndrome is caused by an X-linked genetic defect in the WAS gene, which is located on short arm of the X-chromosome at Xp 11.22-23 position.

The gene product Wiskott-Aldrich protein (WASp) is a 502 amino acid protein that is expressed in the cytoplasm of non-erythroid hematopoietic cells.

More than 300 gene mutations have been identified that result in abnormal protein configuration.

Wiskott-Aldrich syndrome is caused by mutations in the gene WASP (WAS protein), which is involved in actin polymerization, cellular signaling, cytoskeletal rearrangement, and immunological synapse formation.

Individuals with the disease may experience a different number and severity of symptoms.

Bleeding

Immunodeficiency

Eczema

Autoimmune Manifestations

Malignancies

There are three main clinical phenotypic symptoms: –

Classic (severe) Wiskott-Aldrich syndrome

X-linked Neutropenia (XLN)

X-linked Thrombocytopenia (XLT)

Any male with thrombocytopenia, eczema, recurrent respiratory infections, autoimmunity should be evaluated for WAS.

Any male patient with severe congenital neutropenia should be evaluated for XLN.

Abnormal immunologic findings in patients with WAS include: –

Decrease number and function of T cells and regulatory T cells.

Abnormal immunoglobulin (Ig) isotypes.

Defective antigen-antibody response.

Impaired cytotoxicity of natural killer cells with normal to increased cell numbers.

Impaired chemotaxis of neutrophils and phagocytic cells.

Absolute lymphocyte counts are typically normal during infancy, but T and B cell counts decline later in life in people with classic WAS.

Variations in Ig levels, including normal serum IgG levels, decreasing IgM levels, and elevated IgA and IgE levels.

Wiskott-Aldrich syndrome is primarily managed with supportive care, which includes the following: –

Broad-spectrum antibiotics for bacterial infections.

Antivirals/antifungals for viral and fungal infections respectively.

Platelet transfusions to prevent bleeding.

Topical steroids to treat eczema.

Patients with significant antibody deficiency who have WAS or XLT should receive intravenous immunoglobin (IVIG) therapy.

Immunosuppressive therapy may be required for autoimmune manifestations.

In some patients, an elective splenectomy has been suggested as a way to stop the bleeding tendency and reverse the thrombocytopenia by increasing the number of circulating platelets.

HCT is the only available curative treatment.

Gene therapy is a potential alternative treatment for WAS that is currently being researched.

Read more at : https://medicaregate.com/wiskott-aldrich-syndrome-causes-symptoms-treatments/

#immune system diseases #rare diseases #Wiskott-Aldrich Syndrome

[laocommunity]

Kamada's Groundbreaking Q1 2023 Financials: Reveals Surprising Growth and Unveils Exciting Plans for the Future

Kamada's Groundbreaking Q1 2023 Financials: Reveals Surprising Growth and Unveils Exciting Plans for the Future # Kamada's Groundbreaking Q1 2023 Financials: Reveals Surprising Growth and Unveils Exciting Plans for the Future # Introduction Investors and stakeholders have been eagerly waiting for Kamada's Q1 2023 financials, and the numbers have exceeded all expectations. The Israeli-based biopharmaceutical company has reported a significant increase in revenues and profits, impressing both the market and industry insiders. Along with the impressive financials, Kamada has also announced exciting plans for the future that will undoubtedly cement its position as a leader in the biopharmaceutical industry. This article will delve deeper into Kamada's groundbreaking Q1 2023 financials, including the surprising growth and upcoming projects that are sure to pique the interest of investors and pharmaceutical enthusiasts alike. Kamada's Growth Story Kamada's financials have proven to be more than impressive, with the company reporting revenue of $51.6 million, a solid 27% increase compared to the same quarter the previous year. What's even more impressive is the company's net profits of $6.5 million, up 125% from Q1 2022. This growth can be attributed to the success of Kamada's approved products, including the company's flagship product, Glassia®, a flagship treatment for alpha-1 antitrypsin deficiency. Kamada's innovative products have also contributed to this growth, including the company's investigational therapies, such as its plasma-derived immunoglobulin (IgG) for coronavirus. Kamada's earnings per share (EPS) have also exceeded expectations. The company's EPS came in at $0.19, a significant improvement from Q1 2022 when the EPS was just $0.08. Kamada's improving financials are a testament to the company's dedication to innovation, quality, and operational excellence. Kamada's Exciting Plans for the Future Kamada's impressive financials are not the only area the company is excelling. Kamada is committed to continuing the momentum through a series of exciting plans for the future. The Biopharmaceutical company has several ongoing projects related to the expansion of plasma-derived therapeutic products. One of the company's most notable ventures is the development of an inhalable Alpha 1-antitrypsin product for lung conditions such as Chronic Obstructive Pulmonary Disease (COPD). This product is expected to improve the lives of millions of patients worldwide. Additionally, Kamada is working on developing a high-concentration antithrombin product for patients requiring anticoagulant therapy. Kamada's management is also planning for the expansion of manufacturing capabilities and boosting research and development efforts to improve their biopharmaceutical portfolio. Kamada's Financials Impact on Investors Investors will undoubtedly be impressed by Kamada's recent financial performance, as the company's share prices have been skyrocketing. The company has seen a notable increase from $5 per share to $15 per share in the past year. Kamada's financial success, together with the long-term commitment to innovation and growth, has prompted investors to place higher value on their shares, marking the beginning of an exciting new chapter for the company. In addition to this financial success, Kamada expects its new products to be approved in the next few years, a development that will create even more significant financial opportunities for the company. It is a clear sign for investors that the biopharmaceutical sector is experiencing massive growth, and Kamada is leading the way. Frequently Asked Questions (FAQs) 1. What is Kamada? Ans: Kamada is a biopharmaceutical company that specializes in the development, production, and marketing of specialty plasma-derived protein therapeutics. 2. What is Kamada's flagship product? Ans: Kamada's flagship product is Glassia®, which is an FDA-approved treatment for Alpha-1 Antitrypsin Deficiency (AATD). 3. What does Kamada's Q1 2023 financial report reveal? Ans: Kamada's Q1 2023 financials revealed a 27% increase in revenues and a 125% increase in net profits compared to Q1 2022. The company's earnings per share (EPS) were $0.19 compared to $0.08 the previous year. 4. What are Kamada's future plans? Ans: Kamada's future plans include the expansion of their plasma-derived therapeutic products, including an inhalable Alpha 1-antitrypsin product for lung conditions and the development of a high-concentration antithrombin product. The company is also working on expanding their manufacturing capabilities and boosting research and development efforts. 5. Why is Kamada's financial success essential for investors? Ans: Kamada's financial success creates significant investment opportunities that enable investors to realize high returns from their investments. As Kamada continues to invest in new products, the company's market presence and revenue will continue to grow. 6. What is the significance of Kamada's financial performance to the biopharmaceutical industry? Ans: Kamada's financial success and growth are a reflection of the massive growth the biopharmaceutical industry is currently experiencing. It serves as an indicator of the opportunities available in the sector and illustrates that the application of innovation and operational excellence can lead to a high-return business model. Conclusion Kamada's Q1 2023 financials exceeded all expectations, and the company's revenue, net profits, and earnings per share have significantly improved in the past year. The financial performance coupled with Kamada's solid plans for growth are a clear sign that the company is on the path to becoming a leader in the biopharmaceutical industry. Investors and stakeholders can expect Kamada's share prices to continue to rise based on the company's success. Kamada serves as a model for innovation, dedication, and operational excellence, showing us that with the right approach, companies in the biopharmaceutical sector can be a win-win for investors and healthcare consumers. #NEWS Read the full article

[candyswift-ny]

Introduction to Causes, Symptoms, and Treatments of Immunoglobulin A Deficiency

The most prevalent primary immunodeficiency is immunoglobulin A (IgA) deficiency, characterized by the presence of a low level of IgA in the bloodstream.  This disorder increases the possibility of mucous membrane infections in the ears, lungs, sinuses, as well as gastrointestinal tract.

People who suffer IgA deficiency are more likely to develop some immunodeficiency diseases. And studies have shown the functions of IgA for allergic diseases, autoimmune disorders, gastrointestinal (GI) diseases, etc.

What Is IgA?

IgA is the most common immunoglobulin in mucosal tissue in humans, with secretory IgA airway secretions accounting for around half of all IgA airway secretions. IgA is also the second most abundant protein in circulation, with roughly 90% of it occurring in monomeric form. Secretory IgA is often generated first, with systemic antibodies appearing later in the immune reaction. IgA in mucosal tissue has the ability to translocate across epithelial tissue, and to kill viruses intracellularly.

For example, IgA antibodies are found to be able to dominate the early SARS-CoV-2-specific antibody response in the serum, saliva, and bronchoalveolar lavage fluid of SARS-CoV-2-infected patients. This finding makes it possible to use IgA detection as an early diagnosis marker for detecting COVID-19.

What Is IgA Deficiency?

It's worth noting that IgA levels that are somewhat low are not indicative of IgA deficiency. Low IgA levels often indicate a weaker immune system. Poor sleep, allergies, digestive issues, chronic stress, certain medicines are all possible reasons.

A person with IgA deficiency must have a total absence or extremely low levels of IgA in their blood, at the same time with normal IgG and IgM levels.

What causes IgA deficiency?

IgA deficiency is a health condition that affects approximately one out of every five people. This indicates that it is a hereditary condition. It can, in rare situations, also be caused by certain medicines.

What Are the Symptoms of IgA Deficiency?

It's unclear why some individuals suffer several complications as a result of IgA deficit while others have none. The majority of patients with IgA deficiency do not report an increased level in infections. Some patients with IgA deficiency, although not all, are more susceptible to infections of the mucous membranes.

Sinusitis, lung infections, middle ear infections (otitis media), and GI tract infections, such as Giardiasis, are all possible side effects.

IgA deficiency has also been linked to a higher incidence of comorbidities. Various autoimmune disorders, such as certain blood diseases, systemic lupus erythematosus, rheumatoid arthritis, and Graves' disease, are among them. Approximately 20-30% of patients with IgA deficiency develop these disorders.

What Is the Treatment for IgA Deficiency?

The most common therapy for IgA deficiency is to treat infections or any related disorders that may arise. If one has IgA deficiency and recurring infections, he or she should be treated as soon as possible. This can involve antibiotics for bacterial infections.

Vaccinations against common illnesses, such as the seasonal influenza vaccination and the pneumococcal vaccine, are also suggested.